Objectives: The aim of this study is to determine the efficacy and safety of posaconazole in patients with underlying renal impairment.
Introduction
Immunocompromised patients-such as recipients of haematopoietic stem cell transplants (HSCTs) and solid organ transplants, patients infected with the human immunodeficiency virus and patients with cancer who have chemotherapy-induced neutropenia-are at increased risk for invasive fungal infections (IFIs). 1, 2 Despite the availability of many antifungal agents, the prognosis for immunocompromised patients with IFIs is poor. Reported IFI-related mortality rates range from 33% in patients with haematological cancer or candidiasis to $70% or higher in HSCT recipients with aspergillosis, fusariosis or zygomycosis. 1,3 -5 Many of these immunocompromised patients at risk for IFIs have significant underlying renal impairment that is associated with treatment or underlying disease and that can compromise the efficacy and tolerability of conventional antifungal therapy. Different formulations of amphotericin B and azoles that contain cyclodextrins, which are nephrotoxic excipients used in a number of pharmaceutical preparations, have varying degrees of nephrotoxicity that can potentiate the toxic effects of chemotherapeutic agents. 6, 7 Studies have shown that the triazole posaconazole exhibits in vitro, in vivo and clinical activity against a wide variety of yeasts and moulds, including Aspergillus species, 8 -10 and shows efficacy in several models of experimental pulmonary, cerebral and disseminated aspergillosis. 11 -16 In addition, a single-dose pharmacokinetics study in healthy volunteers showed that posaconazole is predominantly eliminated as an unchanged parent drug in faeces. 17 Another single-dose study showed that posaconazole exposure levels are similar in healthy persons and in patients with varying degrees of renal impairment and that, consequently, dosage adjustments are not necessary for patients with chronic renal disease. 18 A large Phase 3, multicentre, open-label trial showed the efficacy of oral posaconazole given in divided doses at 800 mg daily as salvage treatment of invasive aspergillosis and other IFIs in patients with cancer or underlying immunodeficiency and in recipients of HSCT who are intolerant of or who have infection refractory to other antifungal therapies. 10, 19 In the post hoc subanalysis of patients in this Phase 3 study described herein, we determined the efficacy and safety of posaconazole in patients with underlying renal impairment.
Methods

Design
This report presents the findings of a subanalysis of a Phase 3, multicentre, open-label study that evaluated the efficacy and safety of posaconazole in patients with proven or probable IFIs, who were intolerant of or whose infection was refractory to standard antifungal therapies [subanalysis of population in NCT00034658 (www.clinicaltrials.gov)]. An independent, blinded data review committee assessed patients' eligibility, diagnosis and treatment outcomes.
Patient selection
Patients or their legally authorized representative gave signed, written, informed consent, or the informed consent was obtained by means approved by the study investigator's Institutional Review Board or Ethics Committee. Consent must have been given before the first dose of study medication was administered and before any study-related invasive or diagnostic procedure or test was performed.
In the Phase 3 study, 330 patients with proven or probable IFIs according to the European Organization for Research and Treatment of Cancer-Mycoses Study Group criteria 20 received at least one dose of posaconazole orally. Inclusion criteria included proven or probable IFI that was refractory or resistant to standard antifungal therapies [in the case of candidiasis caused by isolates resistant to both fluconazole and amphotericin B as described in the CLSI (formerly the NCCLS) antifungal susceptibility testing document M27-A 21 ] or must have been intolerant of conventional antifungal therapy, or both, to be included in the modified intent-to-treat population in our subanalysis. Intolerance was defined by the presence of renal impairment [serum creatinine (sCR) level greater than twice the upper limit of normal], severe infusion-related toxic effects (or other organ dysfunction) or high risk of toxic effects based on an underlying disease or the use of concomitant nephrotoxic medications, which precluded the use of standard antifungal therapies. Abnormal renal function was defined as a baseline-estimated creatinine clearance (CL CR ) level , 50 mL/min or, if the CL CR was unknown, a baseline sCR level . 2 mg/dL. CL CR was calculated on the basis of the patient's sCR level, age and sex using the Cockcroft -Gault formula of (1402age) Â (weight)/(sCR Â 72) for male patients and (1402age) Â weight Â 0.85/(sCRÂ72) for female patients. 22 Adults or children aged !13 of either gender and any race were eligible for enrolment. Patients were required to have the ability to take study medication orally by swallowing or via a nasogastric tube. Female subjects had to be non-lactating, and, if of childbearing potential, using effective contraception and have a negative pregnancy test within 72 h of the start of the study drug. Patients were excluded if they had serious or severe hypersensitivities to azole antifungal drugs; were taking concomitant medications known to interact with azole antifungals; were taking (or were expected to take) systemic antifungal treatment or vinca alkaloids; had a QTc interval !20% above normal; had hepatic function tests .10Â the upper limit of normal; were previously enrolled in the study; had a life expectancy of ,72 h; were artificially ventilated and unlikely to be extubated within 24 h of entry into the study; had a clinical or laboratory condition that, in the opinion of the investigator, could make the evaluation of the safety and efficacy of posaconazole difficult; or had a concurrent progressive neurological disease (except if due to IFI) apart from multiple sclerosis, transient ischaemic attacks, previous cardiovascular accidents or subarachnoid haemorrhages, stable epilepsy, HIV-associated dementia and cytomegalovirus retinitis.
Treatment
Patients received posaconazole oral suspension (40 mg/mL) for a total daily dose of 800 mg in divided doses (200 mg four times daily while in the hospital and 400 mg twice daily as outpatients). Whenever possible, doses were administered with food or a liquid nutritional supplement to enhance bioavailability. 23 Subjects with Candida infections of the bloodstream; disseminated, metastatic (deep organ) or hepatosplenic candidiasis; or candidal endocarditis were to receive posaconazole for a minimum of 14 days. Patients with other IFIs were to receive posaconazole for a minimum of 28 days. All subjects were to receive posaconazole for at least 7 days after symptom resolution. The maximum treatment duration was to be 12 months.
Efficacy and safety assessments
The primary efficacy endpoint was patient global response status at the end of treatment, as assessed by the data review committee. The study protocol defined a successful outcome as complete response [resolution of all attributable signs and symptoms of IFIs and all radiological, mycologic or bronchoscopic abnormalities (if present at baseline)] or partial response ( partial resolution or observable improvement in any attributable clinical signs and symptoms of IFIs and any radiological, mycologic or bronchoscopic abnormalities). The protocol defined an unsuccessful outcome as stable disease (no improvement in any attributable signs or symptoms of IFIs and radiological, mycologic or bronchoscopic abnormalities) or treatment failure (deterioration in attributable clinical or radiological abnormalities that necessitated alternative antifungal therapy or resulted in death). Data were analysed using descriptive statistics only. The emphasis of the safety assessment was monitoring of adverse events.
Results
Patient characteristics
We identified 65 patients with proven or probable IFIs and renal impairment at baseline for this subanalysis; 59 had a CL CR ,50 mL/min and 6 had an unknown CL CR but a sCR level .2 mg/dL. We compared these patients with 173 patients in the Phase 3 study who also had IFIs but who had greater renal function [i.e. CL CR !50 mL/min (hereafter referred to as acceptable renal function)]. Demographic and baseline characteristics of these patients are shown in Table 1 . In the group with renal impairment, a large number (28) of patients were intolerant of and also had infections refractory to standard antifungal therapy. Table 1 shows that there were no substantial differences between the two groups with regard to underlying conditions of the patients.
Aspergillus was the causative pathogen for IFIs in 41 of the patients with renal impairment (Table 2) . Less common causative pathogens were Candida (n ¼ 5), Fusarium (n ¼ 3), Cryptococcus (n ¼ 6), Coccidioides (n ¼ 2) and the Zygomycetes (n ¼ 3) species. Four patients had infections caused by more than one pathogen.
Most of the patients with impaired renal function (n ¼ 57) received amphotericin B-based preparations before study enrolment. In addition, 23 patients received itraconazole, 3 fluconazole, 3 voriconazole and 1 received an echinocandin before enrolment. Before baseline, 13 patients in this group received tacrolimus, 13 mycophenolate mofetil, 5 foscarnet and 3 cyclosporine. During or within 30 days of the end of treatment with posaconazole, 17 of the patients in the renal impairment group received tacrolimus, 13 mycophenolate mofetil, 8 foscarnet, 4 cyclosporine and 1 rapamycin. The duration of posaconazole-based therapy ranged from 2 to 365 days in the total population.
Efficacy
Overall, patients with renal impairment had a global response rate similar to that of patients with acceptable renal function after treatment of their IFIs with posaconazole (Table 2) . When examined by reason for enrolment, response was similar to the overall rate in both groups. We also observed comparable response rates in the two groups in patients with invasive aspergillosis and those with infections caused by miscellaneous pathogens (e.g. Histoplasma and Pseudallescheria). Relatively few patients with other mycoses had co-existing abnormalities of renal function. Responses in these patients did not seem to be substantially different from those in patients with normal renal function, but the numbers are too small for analysis by pathogen.
Safety
Posaconazole was well tolerated in our population of seriously ill patients with IFIs and underlying renal impairment. Specifically, we observed that 32 of these 65 patients and 72 of 173 patients with acceptable renal function had at least one adverse event that was possibly or probably related to posaconazole-based treatment. The most common treatment-related adverse events are listed in Table 3 . Fourteen patients with renal impairment reported serious adverse events (widely distributed across body systems) that were possibly or probably treatment-related. Seven patients in this group experienced treatment-related adverse events that led to the discontinuation of treatment with posaconazole, discontinuation from the study or death. Treatment with posaconazole was discontinued in one patient because of elevated pancreatic and liver enzyme levels.
We found no apparent temporal relationship between the duration of posaconazole-based therapy and the possible or probable occurrence of a clinically significant drug -drug interaction with a calcineurin inhibitor. Elevated cyclosporine or tacrolimus levels were reported in five patients and were possibly or probably related to treatment with posaconazole. One of the five patients experienced a toxic effect of cyclosporine on day 24 of treatment and subsequently died on day 30; the death was considered unrelated to treatment.
Thirty-three of the patients with renal impairment died. The most common causes of death were considered unrelated to the study treatment. Most of the deaths were caused by complications of the patient's underlying disease or progression of the IFI.
Discussion
This subanalysis of 65 patients in a large multicentre study suggests that posaconazole is a clinically important alternative to current conventional therapy for the treatment of refractory IFIs in subjects with underlying renal impairment. In this population of severely ill patients, the overall response rate in patients with renal impairment who had aspergillosis was consistent with the response rate in patients with aspergillosis in the overall study population (42%). 10 Our study also shows that posaconazole is safe and well tolerated in patients with IFIs and varying degrees of underlying renal impairment. A recently published assessment of the safety of long-term posaconazole-based treatment 24 provided a valuable context for evaluating these findings. Compared with all patients in the overall long-term safety population [38% (164/428)], a higher percentage of patients in the renal impairment subgroup in our study [49% (32/65)] reported adverse events that were possibly or probably related to treatment with posaconazole. In both populations, the most frequently reported treatment-related adverse events were primarily gastrointestinal. In addition, most patient deaths were caused by adverse events attributable to complications of the patient's underlying disease or to progression of the IFI under evaluation. Posaconazole: salvage treatment in IFIs
Overall, posaconazole was well tolerated in this study, even by patients with the most severe renal impairment. In contrast, intravenous formulations of azole antifungals that contain cyclodextrin (such as itraconazole or voriconazole) are not recommended for patients with CL CR ,30 mL/min (itraconazole) or ,50 mL/min (voriconazole). 7 The calcineurin inhibitors cyclosporine and tacrolimus are extensively metabolized by cytochrome P450 enzyme 3A4 (CYP3A4) in the liver and small intestine 25 and are substrates for P glycoprotein. 26 Although posaconazole does not significantly affect CYP1A2, CYP2C8/9, CYP2D6 or CYP2E1 activity, it is an inhibitor of hepatic CYP3A4 activity. 27 Therefore, elevated cyclosporine and tacrolimus plasma levels are expected with posaconazole co-administration, as with other azoles that are CYP3A4 inhibitors. 28 -33 Pharmacokinetics studies have shown that the co-administration of posaconazole increases the levels of cyclosporine and tacrolimus. 34 Therefore, blood levels of tacrolimus and cyclosporine should be carefully monitored during co-administration with posaconazole and after discontinuation of treatment with posaconazole. 35 This subanalysis of patients with underlying renal impairment is limited by its post hoc nature and the lack of actual (rather than estimated) CL CR data for all patients. Nevertheless, the results suggest that the efficacy and safety of posaconazole are similar in patients with renal impairment and in those with normal renal function.
In conclusion, we found that posaconazole was active against aspergillosis and other IFIs in a population of patients with renal impairment, and that it was safe and well tolerated in this population. Posaconazole may be a clinically important alternative to current antifungal agents for the treatment of refractory IFIs in patients with underlying renal disease who have limited therapeutic options. Tacrolimus levels were elevated in three patients, and cyclosporine levels were elevated in two patients. d Tacrolimus level was elevated in one patient.
